These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24195644)

  • 1. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
    Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
    Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
    Diaz CM; Chiappori A; Aurisicchio L; Bagchi A; Clark J; Dubey S; Fridman A; Fabregas JC; Marshall J; Scarselli E; La Monica N; Ciliberto G; Montero AJ
    J Transl Med; 2013 Mar; 11():62. PubMed ID: 23497415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects.
    Facciabene A; Aurisicchio L; Elia L; Palombo F; Mennuni C; Ciliberto G; La Monica N
    Vaccine; 2007 Dec; 26(1):47-58. PubMed ID: 18055074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing vaccine potency through exosome antigen targeting.
    Hartman ZC; Wei J; Glass OK; Guo H; Lei G; Yang XY; Osada T; Hobeika A; Delcayre A; Le Pecq JB; Morse MA; Clay TM; Lyerly HK
    Vaccine; 2011 Nov; 29(50):9361-7. PubMed ID: 22001882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
    Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
    Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
    J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.
    Hartman ZC; Wei J; Osada T; Glass O; Lei G; Yang XY; Peplinski S; Kim DW; Xia W; Spector N; Marks J; Barry W; Hobeika A; Devi G; Amalfitano A; Morse MA; Lyerly HK; Clay TM
    Clin Cancer Res; 2010 Mar; 16(5):1466-77. PubMed ID: 20179231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA.
    Mennuni C; Calvaruso F; Facciabene A; Aurisicchio L; Storto M; Scarselli E; Ciliberto G; La Monica N
    Int J Cancer; 2005 Nov; 117(3):444-55. PubMed ID: 15906358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
    Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
    Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination.
    Quiroga D; Aldhamen YA; Appledorn DM; Godbehere S; Amalfitano A
    Cancer Immunol Immunother; 2015 Apr; 64(4):479-91. PubMed ID: 25655760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.
    Peruzzi D; Dharmapuri S; Cirillo A; Bruni BE; Nicosia A; Cortese R; Colloca S; Ciliberto G; La Monica N; Aurisicchio L
    Vaccine; 2009 Feb; 27(9):1293-300. PubMed ID: 19162112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
    Pakravan N; Hashemi SM; Hassan ZM
    Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection.
    Facciabene A; Aurisicchio L; Elia L; Palombo F; Mennuni C; Ciliberto G; La Monica N
    Hum Gene Ther; 2006 Jan; 17(1):81-92. PubMed ID: 16409127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
    Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.